Incyte Grows Revenue 37.7% at a 15.46 P/E – Can It Outrun the 2028 Jakafi Patent Cliff?

Incyte, the biotech behind the blood-cancer drug Jakafi and the skin treatment Opzelura, closed at $121.35, about 5% below its two-year high of $127.81 and more than double its two-year low of $56.87. The fundamentals behind that run are striking: revenue growth of 37.7% over the trailing twelve months, an operating margin of 41.9% and a P/E of just 15.46. This Incyte stock analysis, based on Yahoo Finance data as of October 1, 2026, explains why the scoring model rates the stock a Buy with a Recommendation Score of 78/100 – and why the biggest risk sits outside the current numbers.

What Is Happening With the Stock Price

At $121.35, Incyte trades in the upper end of its two-year range, and momentum has been driven by results rather than speculation. According to published reports, second-quarter revenue reached $1.67 billion, up 38% year on year and ahead of consensus estimates, and management raised full-year 2026 net product sales guidance to $5.13 billion to $5.26 billion. Notably, Jakafi net sales grew only 7% to $817 million in the quarter, so most of the growth is coming from outside Jakafi – the key question the market is weighing.

Quality: Is This a Financially Sound Business?

Quality scores 98/100, a near-perfect reading in this Incyte stock analysis. Operating margin is 41.9% and net profit margin 27.7%, with earnings per share of $7.85. The 55.7% gross margin is lower than many drugmakers report, which may reflect how costs such as royalties are classified; the operating margin is the better guide to profitability here.

Cash generation is solid. Free cash flow over the trailing twelve months was $1.2 billion, roughly three-quarters of the net income implied by a 27.7% margin on $5.8 billion of revenue, giving a free-cash-flow yield of 4.8%. The balance sheet is close to debt-free, with debt-to-equity of 0.01, a current ratio of 4.59 and a quick ratio of 4.31. Return on equity of 30.7% and return on assets of 16.8% are therefore earned with almost no debt.

Growth: Does This Company Have Real Upside?

Growth scores 76/100, the second-strongest pillar. Revenue rose 37.7% over the trailing twelve months to $5.8 billion, well above the 14.8% five-year CAGR, and earnings grew at the same 37.7% rate, so the expansion is reaching the bottom line rather than being absorbed by costs. On the model’s Rule of 40 test, which adds blended revenue growth to free-cash-flow margin, Incyte scores about 49, comfortably above the benchmark. An EV/Revenue multiple of 3.52 is modest for a company growing at this pace.

The caveat is durability. Published reports indicate that Jakafi’s key US patents expire in 2028, and full-year Jakafi guidance of $3.22 billion to $3.27 billion still represents roughly 60% of guided product sales. Sustaining growth beyond 2028 depends on newer products and the pipeline filling that gap.

Opportunity: Is Now a Good Time to Enter?

Opportunity scores 60/100. A P/E of 15.46 against 37.7% earnings growth gives a P/E-to-growth ratio of about 0.41, which the model rewards. EV/EBITDA of 10.54 and a 4.8% free-cash-flow yield add to the valuation case, and an EV/Revenue of 3.52 versus roughly 4.2 times revenue for the $24.60 billion market capitalization implies a net cash position. Price-to-book of 3.84 is less compelling. Price position holds the score back: with the shares in the upper end of their two-year range, this is a momentum setup rather than a contrarian one. The modest multiples may also reflect the market already pricing in the post-2028 revenue risk.

Incyte Stock Analysis: The Bottom Line

This Incyte stock analysis ends with a model signal of Buy and a Recommendation Score of 78/100, supported by Quality (98/100), Growth (76/100) and Opportunity (60/100). The bull case: 37.7% revenue and earnings growth, a 41.9% operating margin, a near debt-free balance sheet, a 15.46 P/E and a 4.8% free-cash-flow yield. The bear case: heavy reliance on Jakafi ahead of its 2028 patent expiry, growth rates that may not be sustainable, clinical and regulatory risk in the pipeline, and a share price near the top of its two-year range, which leaves less room for disappointment.

The Buy label reflects StreetBriefs’ quantitative scoring model (Quality, Growth, Opportunity) – a data-driven signal for further research, not a personalized recommendation to transact. Biotech revenues can shift quickly on competition, pricing and trial outcomes, and the shares could fall if newer products fail to offset the eventual decline in Jakafi sales.